NOD2 and cirrhosis of liver: Thus, it is the aim of the INCA (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites) trial to investigate whether survival of a genetically defined high-risk group of cirrhotic patients characterized by the presence of NOD2 genetic variation is improved by primary antibiotic prophylaxis of SBP.